Registrati per grafici in tempo reale, strumenti di analisi e prezzi.

Registrati

Quotazioni in diretta

AMRX Amneal Pharmaceuticals Holding Co

5,87

0,00 (0,00%)

Ultimo aggiornamento: 01:00:00

Dati in Delay di 15 minuti

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

05/16/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

DEBORAH AUTOR

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Grafico Azioni Amneal Pharmaceuticals (NYSE:AMRX)
Storico
Da Dic 2024 a Gen 2025

Clicca qui per i Grafici di Amneal Pharmaceuticals

Grafico Azioni Amneal Pharmaceuticals (NYSE:AMRX)
Storico
Da Gen 2024 a Gen 2025

Clicca qui per i Grafici di Amneal Pharmaceuticals

Notizie Amneal Pharmaceuticals Holding Co - AMRX

Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration
Giovedì 5 Settembre 2024 (5 mesi fa) • Business Wire

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials
Martedì 20 Agosto 2024 (5 mesi fa) • Business Wire

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials
Martedì 20 Agosto 2024 (5 mesi fa) • Business Wire

Form 144 - Report of proposed sale of securities
Mercoledì 14 Agosto 2024 (6 mesi fa) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Mercoledì 14 Agosto 2024 (6 mesi fa) • Edgar (US Regulatory)

UBS Beats Earnings Forecasts, Intel Divests Arm Holdings, Flutter Surges 9% in Premarket Trading, and More
Mercoledì 14 Agosto 2024 (6 mesi fa) • IH Market News

Amneal Reports Second Quarter 2024 Financial Results
Venerdì 9 Agosto 2024 (6 mesi fa) • Business Wire

Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules
Mercoledì 7 Agosto 2024 (6 mesi fa) • Business Wire

Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags
Lunedì 29 Luglio 2024 (6 mesi fa) • Business Wire

Amneal to Report Second Quarter 2024 Results on August 9, 2024
Giovedì 11 Luglio 2024 (7 mesi fa) • Business Wire

Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant
Martedì 9 Luglio 2024 (7 mesi fa) • Business Wire

Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar
Lunedì 1 Luglio 2024 (7 mesi fa) • Business Wire

Più Amneal Pharmaceuticals Holding Co Articoli Notizie

Delayed Upgrade Clock

Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US ADVFN Korea